Doctors at Keck Medicine of USC have begun implanting dopamine-producing stem cells into the brains of people with Parkinson\u2019s disease, as part of an early-stage clinical trial designed to assess safety and feasibility. The approach aims to replace nerve cells lost to the disorder and restore dopamine production at its source.<\/p>\n
Parkinson\u2019s is a progressive neurological condition best known for tremor, stiffness and slowed movement, but it can also affect sleep, mood and cognition. In the United States, more than 1 000 000 people are living with Parkinson\u2019s, and roughly 90 000 new cases are diagnosed each year, according to public health estimates.<\/p>\n
The disease is closely tied to the gradual death of dopamine-producing neurons, which disrupts signals that help coordinate movement. Standard treatments, including levodopa and other medications, can reduce symptoms, but they do not reliably stop the underlying neurodegeneration.<\/p>\n
The new strategy attempts to address that core deficit by placing replacement cells directly into brain circuits involved in motor control. Researchers say that if transplanted cells survive and produce dopamine in a regulated way, patients could see more stable symptom control than medication alone can provide.<\/p>\n
The trial uses induced pluripotent stem cells, or iPSCs, which are created by reprogramming adult cells back into a flexible state that can be guided to become specific cell types. In this study, the cells are engineered to mature into dopamine-producing neurons intended to integrate into the brain.<\/p>\n
During surgery, clinicians create a small opening in the skull and use imaging guidance to deliver the cells into the basal ganglia, a region central to movement regulation. Participants are monitored closely after implantation for complications such as infection and abnormal involuntary movements, known as dyskinesia.<\/p>\n
The multi-site U.S. study plans to enroll 12 people with moderate to moderate-severe Parkinson\u2019s disease, with follow-up in the first 12 to 15 months focused heavily on safety signals. Researchers also plan longer observation, up to five years, to evaluate durability and potential longer-term risks.<\/p>\n
The investigational therapy, called RNDP-001, is produced by Kenai Therapeutics, and the FDA has granted the study fast-track designation, a process meant to speed development for serious conditions with unmet need. Even with that designation, researchers caution that larger trials would be required to determine whether the implants provide consistent, meaningful clinical benefit.<\/p>\n
Stem cell and cell-replacement approaches are an active area of Parkinson\u2019s research worldwide, reflecting a broader push to move beyond symptom relief toward disease-modifying strategies. For now, the USC-led effort adds closely watched clinical data on whether implanted dopamine neurons can be delivered safely and function as intended in patients.<\/p>\n","protected":false},"excerpt":{"rendered":"
USC doctors are testing dopamine-producing stem cell implants for Parkinson\u2019s in an early trial, tracking safety, symptoms and long-term results.<\/p>\n","protected":false},"author":0,"featured_media":18825,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[36],"tags":[10016,10018,9775,10017,3811,10015],"miestas":[],"class_list":["post-18824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-psychology","tag-dopaminas","tag-fda-fast-track","tag-kamienines-lasteles","tag-keck-medicine-of-usc","tag-klinikiniai-tyrimai","tag-parkinsono-liga"],"acf":[],"_links":{"self":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/18824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/comments?post=18824"}],"version-history":[{"count":0,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/18824\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media\/18825"}],"wp:attachment":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media?parent=18824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/categories?post=18824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/tags?post=18824"},{"taxonomy":"miestas","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/miestas?post=18824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}